COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities

Rokhsareh Aghili1, Maryam Honardoost*1,2, Mohammad E Khamseh1

Received: 7 Jun 2020  Published: 2 Nov 2020

Abstract

The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.

Keywords: COVID-19, Associated comorbidities, Treatment, ACE2 inhibitors, Type 2 diabetes

Introduction

One of the major challenges in the 21st century is the spread of emerging infectious diseases; namely, the ongoing new Coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) outbreak. COVID-19 as the latest infectious disease has become a pandemic (1-3). Coronavirus identified in the mid-1960s cause disease in humans and a variety of animals; SARS-CoV, and MERS-CoV are 2 coronaviruses causing outbreaks in humans (4). Genetic analysis revealed COVID-19 is very similar to the severe acute respiratory syndrome (SARS) (1, 5). It genetically clusters within the genus betacoronavirus (4); however, discordant clustering with the Bat SARS-like coronavirus sequences has been detected (5). There is evidence that COVID-19 is not mosaic with a distinct lineage in almost half of its genome within the betacoronavirus (5).

The last COVID-19 Situation Report of World Health Organization (WHO) on September 7, 2020, reported 27 million diagnosed cases with 900000 deaths worldwide (6).

The most prevalent comorbidity in the confirmed COVID-19 patients was hypertension, which was found in 1/5 of the patients, consistent with the tendency of the virus binding with ACE2 receptor. Diabetes mellitus (DM) was detected in almost 10%; other comorbidities such as chronic liver disease, kidney, heart, and even lung diseases were present in less than 10% of the patients (7, 8).

COVID-19 infection and case fatality estimates

WHO-China Joint Mission group reported that among
COVID-19, comorbidities, and ACE2 inhibitors

55,924 laboratory confirmed cases, 2,114 cases died since February 20, 2020 (Crude Fatality Ratio [CFR]: 3.8%). Demographic factors, including age and sex, are risk factors for COVID-19 infection. The highest mortality is reported among patients over 80 years (CFR 21.9%) and in men (4.7% vs. 2.8%) (7-9). The lower risk in women could be justified by the plausible protective effect of the X chromosome and sex hormones having a significant contribution in innate and adaptive immunity (10). Furthermore, obesity and presence of comorbidity are associated with significant increase in mortality (10). The CFR is higher in the presence of hypertension (CFR: 8.4%), diabetes (CFR: 9.2%), cardiovascular disease (CFR: 13.2%), chronic respiratory disease (CFR: 8%), and cancer (CFR: 7%). This could be explained by the weaker immune function (9, 10), while in patients without any comorbidity, the CFR was reported to be 1.4% (7-9).

In another report by Chinese Center for Disease Control and Prevention, the CFR was reported to be 0.9% among patients without comorbidity, while this figure was 10.5% for those with cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for hypertension, and 5.6% for cancer (3).

Based on previous published data, the prevalence of important COVID-19 comorbid conditions is summarized in Table 1. Chen et al found about 50% of patients infected with COVID-19 had a comorbidity, mainly cardiovascular/cerebrovascular diseases (40%) and diabetes (12.12%) (3).

In a study on 138 patients, 102 did not receive ICU care, while 36 patients required ICU care due to older age (median age, 66 years [IQR, 57-78] vs 51 years [IQR, 37-62]; P < 0.001) and underlying diseases such as hypertension (21 [58.3%] vs 22 [21.6%), diabetes (8 [22.2%] vs 6 [5.9%]), cardiovascular disease (9 [25.0%] vs 11 [10.8%]), and cerebrovascular disease 6 [16.7%] vs 1 [1.0%]) (13).

Several studies have reported 38.7% to 64.3% of diagnosed COVID-19 patients had at least one chronic medical illness and the most prevalent of which were diabetes and hypertension (Table 1) (14, 15).

**COVID-19 virus exploited host ACE2 receptor**

Coronaviruses are RNA viruses containing at least 4 structural proteins, including the membrane, envelope, spike, and nucleocapsid protein (5, 16). During virus infection, spike facilitates attachment to cellular receptor or attachment factors (17-19). Angiotensin-converting enzyme 2 (ACE2) as one of the membrane exopeptidase acts as a host receptor for COVID-19 to enter the human cells (4, 20). ACE2 as a part of renin-angiotensin-aldosterone system (RAAS) regulates vasoconstriction, sodium reabsorption, and electrolyte balance resulting in blood pressure control (18). Within the RAAS, angiotensin (Ang) I is converted into the vasconstrictor Ang II by ACE, while ACE2 counterbalance the pathway with great affinity to Ang II and transform it to vasodilator Ang 1-7 (18).

Michael Letko et al demonstrated COVID-19 may enter the cell by expressing human ACE2, confirming the role of ACE2 in virus infection (16). High expression of ACE2 in oral cavity and specifically epithelial cells of tongue explains the reason for susceptibility of oral cavity for COVID-19 infection. ACE2 is also highly expressed in lung, esophagus, ileum, colon, cholangiocytes, myocardial cells, renal proximal tubule cells, and bladder urothelial cells, indicating these organs can be affected by COVID-19 infection (21). However, its role in development of lung injury in SARS-Cov infection was controversial because of downregulation of ACE2 expression as infection initiated (14). It might have dual effects: as a receptor for virus entrance and as a lung injury promoter by downregulation (14).

**Treatment modalities targeting host cell receptor and virus entry**

No specific medication or vaccine has been made against COVID-19 yet (22). Two classes of medications are currently used to treat COVID-19: one targets human immune system and the other acts on the Coronavirus itself (19). Considering the potential routes of SARSCoV-2 entrance to the host cell, an effective therapeutic option can be based on the virus-host cell receptor interaction to inhibit the virus entry. The virus uses ACE2 as a receptor to enter the cell; therefore, targeting ACE2 binding may prevent COVID-19 infection (4, 21, 23). Chloro-

---

**Table 1. Prevalence of important comorbid conditions**

<table>
<thead>
<tr>
<th>Laboratory confirmed cases</th>
<th>Cardiovascular disease</th>
<th>Diabetes</th>
<th>Hypertension</th>
<th>Chronic respiratory disease</th>
<th>Cancer</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N)</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>15</td>
<td>20</td>
<td>15</td>
<td>-</td>
<td>-</td>
<td>(10)</td>
</tr>
<tr>
<td>26</td>
<td>19.2</td>
<td>42.3</td>
<td>53.8</td>
<td>19.2</td>
<td>-</td>
<td>(9)</td>
</tr>
<tr>
<td>138</td>
<td>14.5</td>
<td>10.1</td>
<td>31.2</td>
<td>-</td>
<td>7.2</td>
<td>(11)</td>
</tr>
<tr>
<td>36 (ICU admitted)</td>
<td>25</td>
<td>22.2</td>
<td>53.8</td>
<td>-</td>
<td>-</td>
<td>(11)</td>
</tr>
<tr>
<td>102</td>
<td>10.8</td>
<td>5.9</td>
<td>21.6</td>
<td>-</td>
<td>-</td>
<td>(11)</td>
</tr>
<tr>
<td>9</td>
<td>-</td>
<td>11.11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(38)</td>
</tr>
<tr>
<td>140</td>
<td>12.1</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(12)</td>
</tr>
<tr>
<td>1099</td>
<td>2.5</td>
<td>7.4</td>
<td>15</td>
<td>1.1</td>
<td>0.9</td>
<td>(13)</td>
</tr>
<tr>
<td>926 (non severe)</td>
<td>1.8</td>
<td>5.7</td>
<td>13.4</td>
<td>0.6</td>
<td>0.8</td>
<td>(13)</td>
</tr>
<tr>
<td>173 (severe)</td>
<td>5.8</td>
<td>16.12</td>
<td>23.7</td>
<td>3.5</td>
<td>1.7</td>
<td>(13)</td>
</tr>
<tr>
<td>99</td>
<td>40</td>
<td>12.12</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(8)</td>
</tr>
<tr>
<td>44,672</td>
<td>4.2</td>
<td>5.3</td>
<td>12.8</td>
<td>2.4</td>
<td>0.5</td>
<td>(3)</td>
</tr>
</tbody>
</table>

[DOI: 10.34171/mjiri.34.147]
quine, an old drug used to treat malaria, amoebiasis, HIV, and autoimmune diseases has been effective in treatment of COVID-19 (24, 25). It acts via increasing endosomal pH required for viral entrance to the cell. Furthermore, it interferes with the glycosylation of ACE2 (impairment of terminal glycosylation), leading to less affinity between ACE2 and SARS-CoV spike protein and inability of the virus to attach to cell and thus preventing infection initiation (24).

On the other hand, an effective and safe approach is passive immunization (26). Monoclonal antibodies are the important class of medications in immunotherapy with higher specificity, purity, safety, and low risk of contamination compared to serum therapy and intravenous immunoglobulins.

Considering the results of the study conducted by Khan et al on patients with ARDS, GSK2586881, a recombinant human ACE2 (rhACE2), resulted in a decrease in plasma Ang II and IL-6 and increase in Ang 1-7 (27, 28). Therefore, it could potentially be used for severe COVID-19. Viral/host-targeted agents; their mechanism of action are summarized in Table 2.

**ACE2-based therapy: The link between infection susceptibility and treatment controversially**

Under-glycosylation of ACE2 by using chloroquine may prevent virus infection. On the other hand, it may interfere with the normal function of ACE2 and lead to cardiovas-

### Table 2: Summary of potential antiviral agents against COVID-19 based on targeting virus-receptor binding and virus entry

<table>
<thead>
<tr>
<th>Infectious diseases</th>
<th>Antiviral agents</th>
<th>Reported mechanism of action</th>
<th>Action status</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019-nCoV, MERS-CoV</td>
<td>Nafamostat</td>
<td>Inhibits spike-mediated membrane fusion</td>
<td>Approved for anticoagulant therapy in Asian countries</td>
</tr>
<tr>
<td>SARS-CoV</td>
<td>Griffithsin (red-alga-derived lectin)</td>
<td>Inhibits viral entry. Docking results showed that glycyrrhizin has the potential binding to ACE2.</td>
<td>Phase I for the prevention of HIV transmission</td>
</tr>
<tr>
<td>SARS-CoV</td>
<td>Glycyrrhizin (liquorice root)</td>
<td>Inhibits viral entry. Docking results showed that glycyrrhizin has the potential binding to ACE2.</td>
<td>Clinical trials for treatment of liver diseases [63]</td>
</tr>
<tr>
<td>SARS-CoV, MERS-CoV, Influenza</td>
<td>Peptide (P9)</td>
<td>Inhibits spike protein-mediated cell-cell entry or fusion</td>
<td>Preclinical</td>
</tr>
<tr>
<td>HCoV (e.g. MERS, SARS)</td>
<td>OC43-HR2P (most promising EK1)</td>
<td>Inhibits pan-CoV fusion</td>
<td>Preclinical</td>
</tr>
<tr>
<td>HCoV-229E</td>
<td>229E-HR1P 229E-HR2P</td>
<td>Inhibits spike protein-mediated cell-cell fusion</td>
<td>Preclinical</td>
</tr>
<tr>
<td>HCoV, Influenza virus</td>
<td>1-thia-4-azaspiro[4.5] decan-3-one derivatives (Compound 8n)</td>
<td>-</td>
<td>Preclinical</td>
</tr>
<tr>
<td>2019-nCoV SARS-CoV MERS-CoV</td>
<td>Chloroquine</td>
<td>Elevates the endosomal pH, and appears to interfere with terminal glycosylation of ACE2. Thus affects the viral fusion and trafficking events.</td>
<td>Approved for malaria and certain amoeba infections Open-label trial for 2019-nCoV (ChiCTR2000029609)</td>
</tr>
<tr>
<td>SARS-CoV 2019-nCoV</td>
<td>SSAA09E2</td>
<td>Blocks early interactions of SARS-S with the receptor for ACE2</td>
<td>Preclinical</td>
</tr>
<tr>
<td>SARS-CoV 2019-nCoV</td>
<td>SSAA09E3</td>
<td>Prevents fusion of the viral membrane with the host cellular membrane</td>
<td>Preclinical</td>
</tr>
<tr>
<td>SARS-CoV 2019-nCoV</td>
<td>NAAE</td>
<td>Inhibits both ACE2 catalytic activity and S-protein-induced cell-cell fusion</td>
<td>Preclinical</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>TMPRSS2 inhibitor</td>
<td>Inhibits viral S protein cleavage and does not allow the fusion of viral and cellular membranes</td>
<td>The protease inhibitor camostat mesylate, which blocks TMPRSS2 activity has been approved in Japan for human use, but for an unrelated indication.</td>
</tr>
<tr>
<td>Coronavirus</td>
<td>R80-GSK2586881</td>
<td>Recombinant human ACE2 which resulted in a rapid decrease in plasma Ang II levels and increase in Ang 1-7 levels</td>
<td>Phase II trial examining the safety and efficacy in patients with ARDS.</td>
</tr>
</tbody>
</table>
ACE2 dysfunction results in elevated concentration of Ang II, which increases oxidative stress and inflammation and could lead to development of metabolic syndrome, diabetes, and diabetes-related complications (29). ACE2/Ang(1–7) pathway has the protective effect in patients with type 2 diabetes and can be a treatment strategy in Ang-II-mediated T2DM through modulating blood glucose by adjusting the levels of Ang II and/or Ang-(1-7) in pancreatic cells and regulating insulin secretion (31-33) (Fig. 1).

Diabetic cardiomyopathy: Cardiovascular disease is highly prevalent in patients with diabetes compared to the general population. RAAS activation and imbalance in ACE-Ang II and ACE2-Ang 1–7 are highly accused in this process (18). High blood glucose can promote local Ang II production in heart tissue. RAAS is also upregulated in diabetes and can lead to activation of AngII pathway and subsequently inflammation, increased oxidative stress, cell proliferation, apoptosis, and fibrosis, which contribute to cardiac remodeling and atherosclerosis. However, ACE2 improves cardiac function by preventing myocardial fibrosis, reducing remodeling, and developing left ventricular hypertrophy and pressure-overload-induced heart failure (23). Therefore, RAAS inhibition by ACE inhibitors and angiotensin II receptor blockers has been recommended as the first line therapy in CVD in patients with diabetes by lowering target-organ damages well as controlling blood pressure (18, 23) (Fig. 1).

Diabetes and hypertension: ACE2 is also present in endothelium of blood vessels; therefore, its reduction could result in increased Ang II level and contribute to elevated blood pressure (34). In a study on rats, overexpression of ACE2 in the blood vessels improved endothelial function leading to reduced blood pressure, while ACE2 deficiency could contribute to increased systolic blood pressure (34, 35). Furthermore, central hypertension can be affected by the level of ACE2 (35). Therefore, ACE2 replenishing may be a significant therapeutic approach against diabetic hypertension.

Diabetic nephropathy: Diabetic nephropathy is a microvascular diabetes-related complication associated with CVD risk in patients with diabetes. Normally, ACE2 is expressed in the kidney predominantly at the luminal brush border of the proximal tubule, while in patients with diabetic nephropathy as well as other forms of chronic kidney disease, ACE2 expression may downregulate and result in albuminuria or tubular injury. Therefore, further renal injury will occur with more ACE2 inhibition (35). In a study conducted by Harris et al, the ACE/ACE2 ratio was found to be increased in both glomerulus and tubulointerstitium of patients with diabetic nephropathy, which is mostly due to reduced ACE2 expression (36). Another study on diabetic mice showed total ACE2 reduction/deletion and pharmacologic ACE2 inhibition may result in diabetic nephropathy (31). However, ACE2 can reduce the progression of diabetic nephropathy by direct effect on glomerulus (36) (Fig. 1).

Diabetic Retinopathy: The most prevalent microvascular diabetes-related complication is diabetic retinopathy (DR) in which abnormal activity of the RAAS has an essential role (29). In contrast, overexpression of ACE2/Ang-(1-7) may have a protective role against DR.

Fig. 1. RAAS and ACE/ACE_2 effects on T2D and associated complications
Animal studies revealed ACE2 as the counter-regulator of Ang II can reduce the intraocular pressure in addition to inflammatory process (29, 38). In line with the results, treatment with recombinant ACE2 could decrease inflammatory process, reduce acellular capillaries, and prevent retinal ganglion cell loss (38). Therefore, it seems increasing the bioavailability of ACE2 has a critical role in treating diabetes-related complications (38) (Fig. 1).

**Conclusion**

The occurrence and development of COVID-19 infection depends on viral factors and host individual factors, including genetics, age, gender, nutrition, and health status (39-41).

Patients with associated comorbidities comprise a high-risk group for Coronavirus infection. The morbidity and mortality are higher in this high-risk patients compared to healthy individuals.

COVID-19 entry to the host cell depends on ACE2 receptor; therefore, a potential treatment strategy for COVID-19 could be inhibiting the ACE2 receptor. However, this may have a negative impact on associated comorbidities such as diabetes and hypertension that are treated with ACE inhibitor (42) because of the protective effect of ACE2/Ang1-7 pathway in patients with type 2 diabetes as well as treatment strategies in Ang-II-mediated T2DM (31-33). In addition, ACEIs upregulate ACE2, which can accelerate viral uptake and colonization in the host’s cells (43). Viral attachment to ACE2 via the spike protein results in ACE2 downregulation and excessive production of Ang II and lower level of Ang 1-7, which in turn leads to lung damage through Angiotensin II receptor type 1 (AT1R) stimulation (22). Increased RAS activity with enhanced AT1R stimulation is a major injury factor affecting the cardiovascular and renal function, lipid and glucose metabolism, the immune system, and more to the point, inflammatory lung disease. AT1R blocking directly reduces inflammation, organ fibrosis and endothelial injury, protects mitochondrial function, maintains insulin sensitivity and energy metabolism, protects lipid metabolism and normalizes the coagulation cascade; these properties are considered to benefit patients with acute critical disorders (44). Therefore, AT1R blockers are suggested to lower the rate of complications and mortality in COVID-19 (22).

Moreover, there are many other therapeutic approaches, such as recombinant soluble ACE2, with less complications mainly in presence of comorbid conditions. Overall, serious efforts must be made to choose an effective treatment for COVID-19 infection, particularly in patients with diabetes.

**Conflict of Interests**

The authors declare that they have no competing interests.

**References**


COVID-19, comorbidities, and ACE2 inhibitors


http://mjiri.iums.ac.ir
Med J Islam Repub Iran. 2020 (2 Nov); 34:147.